Latest Active Biotech News & Updates

See the latest news and media coverage for Active Biotech. We track all announcements, press releases, and industry mentions in real time, all in one place.

Active Biotech

Biotechnology company developing treatments for cancer and inflammatory eye diseases

activebiotech.com

Headquarters: Lund, Sweden
Founded year: 1998
Company type: Public company
Number of employees: 2–20
Industry: Pharmaceuticals

Last updated Today

Latest news about Active Biotech

In short: Active Biotech reduced its operating losses and reached key clinical milestones for tasquinimod in myelofibrosis treatments.

Company announcements

August 18 Active Biotech

Active Biotech expands collaboration in the US with Mount Sinai

The collaboration aims to accelerate clinical development of tasquinimod for myelofibrosis. A preclinical program is launched to validate the drug's effect.

July 24 Active Biotech

Active Biotech announced first patient dosed in amended HO172 study

The Phase Ib/II study evaluates tasquinimod in myelofibrosis patients refractory to JAK2 inhibitors, with greater dosing flexibility.

June 30 Active Biotech

Active Biotech reports post-split share and vote count

As of June 30, 2026, total shares and votes are 26,360,671.

May 28 Active Biotech

Active Biotech announces timetable for reverse share split

The record date is June 4, 2026, and the last day of trading before the split is June 2.

Media coverage

August 20 ZoneBourse

Active Biotech reports a reduction in its operating loss

The research company Active Biotech, as expected, does not publish any revenue for the second quarter of 2026. However, the operating loss has decreased by...

July 23 FinanzNachrichten.de

Active Biotech AB: First patient dosed in the amended HO172 clinical study of tasquinimod in myelofibrosis

Lund Sweden, July 24, 2026 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been dosed in the Phase Ib/II clinical...

May 28 FinanzNachrichten.de

Active Biotech AB: Active Biotech announces timetable for reverse share split

The Annual General Meeting in Active Biotech AB (publ) ("Active Biotech" or the "Company") held on May 20, 2026, resolved to carry out a reverse...

May 19 Salisbury Post

Unaudited Preliminary Results for the Year Ended December 31, 2025

LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated...

Never miss news about Active Biotech

Track Active Biotech and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Active Biotech competitors & trending companies

Browse news for competitors to Active Biotech and other trending companies.